Literature DB >> 16077187

Non A beta component of Alzheimer's disease amyloid and amyloid beta peptides evoked poly(ADP-ribose) polymerase-dependent release of apoptosis-inducing factor from rat brain mitochondria.

A Adamczyk1, G A Czapski, H Jeśko, R P Strosznajder.   

Abstract

Amyloid beta peptide (A beta) and non-A beta component of Alzheimer's disease amyloid (NAC) are involved in pathomechanism of Alzheimer's Disease (AD) and are deposited in the AD brain in the form of senile plaques. However, the mechanism of their neurotoxicity is not fully understood. In this study the sequence of events involved in NAC and A beta peptides evoked toxicity was investigated in brain slices, synaptosomes and in subcellular fractions. Radio-, immunochemical, spectrophotometrical methods and DNA electrophoresis were used in this study. Our data indicated that A beta 1-40 (25 microM) and NAC (10 microM) peptides induced liberation of free radicals and massive DNA damage that lead to activation of DNA bound enzyme poly(ADP-ribose) polymerase-1 (PARP-1). In consequence of these processes apoptosis-inducing factor (AIF) was released from mitochondria and was translocated to nucleus. The inhibitor of PARP, 3-aminobenzamide significantly decreased AIF release from mitochondria and its translocation. Both peptides under the investigational conditions had no effect on caspase-3 activity. Our data indicated that A beta and NAC peptides stimulate AIF-dependent apoptotic pathway that seems to be caspase independent process. The inhibition of PARP-1 may protect the brain against A beta and NAC toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16077187

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  10 in total

Review 1.  Natural inhibitors of poly(ADP-ribose) polymerase-1.

Authors:  Marek Banasik; Todd Stedeford; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2012-04-04       Impact factor: 5.590

Review 2.  Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease.

Authors:  Joanna B Strosznajder; Grzegorz A Czapski; Agata Adamczyk; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2012-03-20       Impact factor: 5.590

3.  The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.

Authors:  Xin Wang; Ana Sirianni; Zhijuan Pei; Kerry Cormier; Karen Smith; Jiying Jiang; Shuanhu Zhou; Hui Wang; Rong Zhao; Hiroko Yano; Jeong Eun Kim; Wei Li; Bruce S Kristal; Robert J Ferrante; Robert M Friedlander
Journal:  J Neurosci       Date:  2011-10-12       Impact factor: 6.167

Review 4.  Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide.

Authors:  Faqi Li; Zhao Zhong Chong; Kenneth Maiese
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

5.  Lipoxygenases and poly(ADP-ribose) polymerase in amyloid beta cytotoxicity.

Authors:  Joanna B Strosznajder; Magdalena Cieslik; Magdalena Cakala; Henryk Jesko; Anne Eckert; Robert P Strosznajder
Journal:  Neurochem Res       Date:  2011-02-02       Impact factor: 3.996

Review 6.  Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.

Authors:  Rosella Abeti; Michael R Duchen
Journal:  Neurochem Res       Date:  2012-10-18       Impact factor: 3.996

7.  Two small enzyme isoforms mediate mammalian mitochondrial poly(ADP-ribose) glycohydrolase (PARG) activity.

Authors:  Ralph G Meyer; Mirella L Meyer-Ficca; Clifford J Whatcott; Elaine L Jacobson; Myron K Jacobson
Journal:  Exp Cell Res       Date:  2007-04-19       Impact factor: 3.905

8.  Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity.

Authors:  Przemysław L Wencel; Walter J Lukiw; Joanna B Strosznajder; Robert Piotr Strosznajder
Journal:  Mol Neurobiol       Date:  2017-07-12       Impact factor: 5.590

Review 9.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

Review 10.  Selenium in the Therapy of Neurological Diseases. Where is it Going?

Authors:  Agnieszka Dominiak; Anna Wilkaniec; Piotr Wroczyński; Agata Adamczyk
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.